– USA, PA – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, today announced the appointment of Stephen E. Butts to its Board of Managers.
Mr. Butts has over 25 years of experience in the pharmaceutical and biotechnology industry, with prominent roles in fundraising, product licensing, and M&A with start-up companies.
“We are delighted to welcome Steve to Knopp Biosciences’ Board of Managers,” said CEO, Dr Michael Bozik. “Steve’s remarkable success as an entrepreneur and company builder coupled with his impressive track record in business development and commercial operations will be instrumental as we work to deliver products from our breakthrough platform to patients with respiratory and rare neurological disorders.”
About Steve Butts
Mr. Butts is currently the co-founder and CEO of Arrivo BioVentures, LLC, a drug development company located in North Carolina. Previously, he served as the CEO of Velo Bio, a clinical-stage company with a product for preeclampsia acquired by AMAG Pharmaceuticals in 2018. Prior to Velo, he was co-founder, President, and COO of Aerial BioPharma LLC, a drug development company that sold its lead drug for narcolepsy to Jazz Pharmaceuticals in 2014. Early in his career, Mr. Butts served as Vice President of Sales & Marketing at BioBehavioral Diagnostics Company, as well in assignments at Eli Lilly and Company and Braintree Laboratories.
“I’m thrilled to join the Board of Knopp during this important time,” Mr. Butts said. “The company has great momentum and is well-positioned to deliver on the potential of the life-changing medicines in its portfolio.”
He holds a BS degree in Business Administration and an MBA from the Kenan-Flagler School of Business at UNC-Chapel Hill.
About Knopp Biosciences
Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs. Knopp’s clinical-stage small molecule, dexpramipexole, has entered Phase 2 clinical trials in eosinophilic asthma and is also slated for Phase 3 development in hypereosinophilic syndrome. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain.
For more information: https://knoppbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
